CYTK:NSD-Cytokinetics, Incorporated (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 28.83

Change

+0.06 (+0.21)%

Market Cap

USD 2.47B

Volume

1.52M

Avg Analyst Target

USD 41.57 (+44.20%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company is developing small molecule drug candidates primarily engineered to increase muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a novel fast skeletal muscle troponin activator, which is in Phase II clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops reldesemtiv that is in Phase II clinical trials in patients with chronic obstructive pulmonary disease, and in Phase Ib clinical trials in elderly subjects with limited mobility. In addition, it develops CK-3773274 (CK-274), a novel cardiac myosin inhibitor, which is in Phase II clinical trial for the potential treatment of hypertrophic cardiomyopathy; CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and CK-3772271 (CK-271), a novel cardiac myosin inhibitor that is in Phase I clinical trial. The company has a strategic alliance with Astellas Pharma Inc. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-08-03 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

+39.90 (+11.51%)

USD141.98B 237.00 190.09
BNTX BioNTech SE

+11.60 (+3.41%)

USD79.30B 59.35 50.07
REGN Regeneron Pharmaceuticals, Inc

+9.38 (+1.63%)

USD61.22B 16.36 12.83
VRTX Vertex Pharmaceuticals Incorpo..

+1.73 (+0.87%)

USD52.23B 26.58 13.36
ALXN Alexion Pharmaceuticals, Inc

N/A

USD40.34B 59.23 42.56
GMAB Genmab A/S

+1.09 (+2.41%)

USD29.62B 33.28 3.77
BGNE BeiGene, Ltd

+14.03 (+4.29%)

USD29.25B N/A N/A
SGEN Seagen Inc

+3.95 (+2.56%)

USD27.91B 47.87 38.34
RPRX Royalty Pharma plc

+0.47 (+1.26%)

USD23.19B 31.49 13.92
ALNY Alnylam Pharmaceuticals, Inc

+0.85 (+0.48%)

USD21.03B N/A N/A

ETFs Containing CYTK

Symbol Name Weight Mer Price(Change) Market Cap
LABU Direxion Shares ETF Trust.. 0.00 % 1.02 %

+1.14 (+2.06%)

USD0.77B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 38.74% 85% B 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 38.74% 85% B 83% B
Trailing 12 Months  
Capital Gain 30.93% 71% C- 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.93% 71% C- 50% F
Trailing 5 Years  
Capital Gain 143.09% 79% C+ 76% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 143.09% 79% C+ 75% C
Average Annual (5 Year Horizon)  
Capital Gain 27.20% 60% D- 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.20% 60% D- 73% C
Risk Return Profile  
Volatility (Standard Deviation) 52.26% 60% D- 34% F
Risk Adjusted Return 52.06% 78% C+ 70% C-
Market Capitalization 2.47B 86% B 77% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 450.00 4% F 4% F
Price/Book Ratio 36.02 5% F 3% F
Price / Cash Flow Ratio 276.25 0% N/A 2% F
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -1,219.69% 3% F 10% F
Return on Invested Capital -96.99% 19% F 8% F
Return on Assets -15.62% 72% C- 22% F
Debt to Equity Ratio 40.75% 28% F 44% F
Technical Ratios  
Short Ratio 11.97 8% F 4% F
Short Percent 12.78% 17% F 14% F
Beta 1.38 48% F 35% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector